A carregar...
Global Proteome Quantification for Discovering Imatinib-induced Perturbation of Multiple Biological Pathways in K562 Human Chronic Myeloid Leukemia Cells
Imatinib mesylate, currently marketed by Novartis as Gleevec in the US, has emerged as the leading compound to treat chronic phase of chronic myeloid leukemia (CML), through its inhibition of Bcr-Abl tyrosine kinase, and other cancers. However, resistance to imatinib develops frequently, particularl...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2974763/ https://ncbi.nlm.nih.gov/pubmed/20949922 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/pr100814y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|